Australia's most trusted
source of pharma news
Wednesday, 05 November 2025
Posted 5 November 2025 AM
Sandoz has announced the PBS listing of Methylphenidate Sandoz XR, a bioequivalent of Johnson & Johnson's Concerta for the treatment of ADHD, which has been the subject of frustrating supply problems.
Reimbursement covers tablets containing 18 mg, 27 mg, 36 mgand 54 mg methylphenidate hydrochloride. Methylphenidate Sandoz XR is a modified-release formulation.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.